Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May-Jun;45(3):61-64.
doi: 10.1097/WNF.0000000000000501.

The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study

Keisuke Suzuki  1 , Kei Funakoshi, Hiroaki Fujita, Koichi Hirata
Affiliations
Clinical Trial

The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study

Keisuke Suzuki et al. Clin Neuropharmacol. 2022 May-Jun.

Abstract

Background: We hypothesized that rotigotine may have a positive effect on cognitive function in patients with Parkinson disease (PD) by improving daytime motor function and sleep status.

Methods: Fifteen PD patients with sleep disturbances, defined as a PD Sleep Scale (PDSS)-2 score of 15 or greater, were included in this single-center, 3-month open-label study. Participants received 2 to 4 mg/24 h (patch content: 4.5-9 mg) rotigotine for a 3-month period. At baseline and 3 months, the patients were evaluated on the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts III and IV and cognitive assessments, such as the Mini-Mental State Examination, frontal assessment battery, and Montreal Cognitive Assessment (MoCA). The Epworth Sleepiness Scale (ESS) and PDSS-2 were administered at baseline and at 1, 2, and 3 months.

Results: At 3 months, the MDS-UPDRS part III (-11.1, P < 0.0001) and MDS-UPDRS part IV (-1.1, P = 0.0013) scores significantly decreased, and off time significantly decreased (-34.6 minutes, P = 0.0085) from baseline. The PDSS-2 scores significantly decreased from baseline at 1 month (-4.2, P < 0.01), 2 months (-7.7, P < 0.0001), and 3 months (-7.3, P < 0.0001). The ESS also decreased at 1 month (-2.5, P < 0.05) and 3 months from baseline (-4.5, P < 0.01). The MoCA scores (1.6, P = 0.0029) significantly improved, but the Mini-Mental State Examination or frontal assessment battery scores did not significantly change. The mean changes from baseline to 3 months in the MoCA were negatively correlated with mean changes in the ESS scores.

Conclusions: We suggest that rotigotine could improve cognitive function by improving motor symptoms, sleep disturbance, and daytime sleepiness in patients with PD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Changes in the MDS-UPDRS III and IV, off time, ESS, PDSS-2 and MoCA scores after rotigotine treatment. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. Error bars represent standard errors of the mean.
See this image and copyright information in PMC

References

    1. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435–450. - PubMed
    1. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009;24(Suppl 2):S656–S664. - PubMed
    1. Woitalla D Dunac A Safavi A, et al. . A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. Expert Opin Pharmacother 2018;19:937–945. - PubMed
    1. Nomoto M Mizuno Y Kondo T, et al. . Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neurol 2014;261:1887–1893. - PubMed
    1. Trenkwalder C Kies B Rudzinska M, et al. . Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90–99. - PMC - PubMed

Publication types